Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06492460

2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

The main objective of this trial was to determine the value of 2 courses of cisplatin concurrent chemotherapy in postoperative adjuvant radiotherapy for high-risk head and neck squamous cell carcinoma.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Loading trial locations.

About this study

The main objective of the trial was to evaluate whether the 3-year failure-free survival (FFS) rate in patients with high-risk head and neck squamous cell carcinoma treated with adjuvant radiotherapy and 2 courses of concurrent cisplatin chemotherapy after surgery was no less than 10% compared with 3 courses of concurrent cisplatin chemotherapy. The secondary objective was to evaluate efficacy and toxicity of 2 courses of concurrent cisplatin chemotherapy (100mg/m2, days 1 and 22) during adjuvant intensity-modulated radiation therapy will be compared with 3 courses of concurrent cisplatin chemotherapy (100mg/m2, days 1, 22 and 43).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A. The pathological type is head and neck squamous cell carcinoma

  • Stages III and IV

B. Radical surgery has been performed with high risk factors (one of below)

  • extracapsular invasion of cervical metastatic lymph nodes
  • positive incisional margin or inadequate incisional margin safety distance

C. No evidence of distant metastasis (M0).

D. Functional status: Karnofsky scale (KPS) > 70.

E. Normal bone marrow function:

  • white blood cell count > 4×109/L
  • hemoglobin > 120g/L in males, 110g/L in females
  • platelet count > 100×109/L

G. Normal liver function:

  • alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 1.5 times the upper limit of normal (ULN)
  • alkaline phosphatase (ALP) < 2.5×ULN
  • bilirubin < ULN.

H. Normal renal function: creatinine clearance > 60 ml/min.

I. Patients must be informed of the basic contents of this study and sign informed consent.

Exclusion criteria

A. Age >70 years or <18 years.

B. Treatment is palliative.

C. Previous chemotherapy (except induction chemotherapy prior to surgery).

D. Previous radiation therapy.

E. Women who are pregnant or breastfeeding

F. Previous history of malignant tumor.

G. With other serious medical conditions that may pose a greater risk or affect compliance with the test. Examples include:

  • unstable heart disease that requires treatment
  • kidney disease
  • chronic hepatitis
  • poorly controlled diabetes (fasting blood glucose > 1.5×ULN)
  • mental illness.

Treatment and study plan

Drug:Cisplatin

Drug

Concurrent Cisplatin chemotherapy (100 mg/m2 intravenous injection,once every 3 weeks, twice in total, on days 1 and 22) will be given plus intensity modulated radiotherapy

Other names: CDDP Drug

Primary outcomes

  1. Failure-free survival (FFS)

    Time frame: 3 years

    calculated from enrolment to the date of locoregional recurrence,distant metastasis,or death from any cause, whichever occurred first.

Secondary outcomes

  1. Overall survival (OS)

    Time frame: 3 years

    calculated from enrolment to the date of death from any cause.

  2. Distant metastasis-free survival(DMFS)

    Time frame: 3 years

    calculated from enrolment to the date of first distant metastasis.

  3. locoregional recurrence-free survival (LRRFS)

    Time frame: 3 years

    calculated from enrolment to the date of locoregional persistence or 1st locoregional recurrence.

  4. Quality of life (QoL)

    Time frame: 3 years

    The change of QoL from randomization to the start of radiotherapy,the end of radiotherapy,13-16 weeks after radiotherapy,2 years and 3 years after randomization. The EORTC QoL questionnaire-C30(EORTC quality of life questionnaire-C30#version 3.0 will be used. This questionnaire comprises 30 questions,24 of which are aggregated into nine multi- question scales,that is,five functioning scales (e.g.,physical),three symptom scales (e.g.,fatigue)and one global health status scale. The remaining six single-question (e.g.,dyspnoea)scales assess symptoms. These 15 scales will be scored according to the official Scoring Manual.

Study contacts

Contact information is provided by the study sponsor or research team.

Lei Chen, M.D

CONTACT

[email protected]

+862013570051477

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Collaborators

  • Guilin Medical University, China
  • Hunan Cancer Hospital
  • Jiangsu Cancer Institute & Hospital
  • Xiangya Hospital of Central South University

Registry information

Official study title

A Multicenter, Randomized Controlled, Non-inferior Phase 3 Clinical Trial of 2 Courses of Concurrent Cisplatin Chemoradiotherapy Versus 3 Courses After Surgery for High-risk Head and Neck Squamous Cell Carcinoma

Important dates

Study start
2024
Primary completion
2029
Study completion
2033
First posted
Jul 9, 2024
Registry last updated
Aug 14, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.